

[Artesunate + mefloquine](#)

Essential medicine status

Section:

[6. Anti-infective medicines](#) [6.5. Antiprotozoal medicines](#) [6.5.3. Antimalarial medicines](#) [6.5.3.1. Antimalarial medicines > Medicines for curative treatment](#)

ATC codes: [P01BF02](#)

EMLc

Indication

Malaria due to Plasmodium vivax ICD11 code: [1F81](#)

INN

Artesunate + mefloquine

Medicine type

Biological agent

List type

Core

Formulations

Oral > Solid > tablet: 25 mg + 50 mg (as hydrochloride) ; 100 mg + 200 mg (as hydrochloride)

EML status history

First added in 2013 ([TRS 985](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Artesunate + mefloquine](#)

DrugBank

[Artesunate](#),

[Mefloquine](#)

Summary of evidence and Expert Committee recommendations



Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - to modify the listing to refer to the strength of mefloquine as the hydrochloride salt.